Several commercial NIPT providers in the US said they are planning to participate in the new program.
CEO David King said that the acquisition of Sequenom positions LabCorp as a leader in NIPT, women's health, and reproductive genetics.
The $302 million deal, which was expected to close by the end of the year, passed US government antitrust review in August.
The deal is still subject to other closing requirements including meeting a minimum tender condition.
Sequenom, which will be acquired by LabCorp this year, saw an increase in testing for average-risk pregnancies in the quarter, despite lower overall revenues.
The firm, as indicated by its agreement to acquire Sequenom, is optimistic about the prospects for NIPT.
LabCorp plans to acquire all of Sequenom's outstanding stock for $2.40 per share.
Although Sequenom had garnered support from a diverse range of groups who wanted clarity on patent eligibility, the Supreme Court denied the petition.